Fierce Healthcare August 11, 2020
Heather Landi

Adaptive Biotechnologies and tech giant Microsoft first teamed up in 2018, they were using cloud computing to “decode” the immune system.

Using immuno-sequencing, proprietary computational modeling, and machine learning, the companies began working on an atlas mapping out the interactions between the immune system and multiple diseases. This makes it possible to “read” what an immune system has fought or is currently fighting, such as certain cancers, the companies said.

The goal of the partnership was to use the biotech company’s immune sequencing capabilities combined with Microsoft’s cloud computing to create a universal blood test that reads a person’s immune system to diagnose and treat diseases.

But now, in the midst of the COVID-19 pandemic, the scope of that...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Pharma / Biotech, Public Health / COVID, Technology
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article